Hi, what are you looking for?
Jewish Business News
Search results for " Yitzhak Peterburg"
Business
Last week Teva CEO, Erez Vigodman said, “If the Mylan Pharmaceuticals shareholders support the acquisition of Perrigo, Teva will abandon its bid for Mylan.”
Business
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) CEO Erez Vigodman said today, “If the Mylan Pharmaceuticals shareholders support the acquisition of...
Business
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has completed first step to buy its rival Mylan N.V. (Nasdaq: MYL). The Israeli giant announced...
Business
Teva is now close to the 4.6% stake in Mylan that will give it standing in the Netherlands courts.
Business
Abbott Laboratories (NYSE: ABT), said it would back the generic pharmaceutical company Mylan’s (MYL) $34 billion bid acquisition of Perrigo Co Plc (PRGO.N). Abbott...
Business
A Credit Suisse study finds that most hostile bids fail, especially if antitrust concerns are involved.
Leadership & A-List
The Teva shareholder and digital printing pioneer thinks Teva should be investing in innovation, not cheap commodity drugs.
Business
[FULL LETTER] After Mylan Responded aggressively to Teva's bid, Erez Vigodman says in an open letter to Robert Coury: Shareholders won't benefit from Mud...
Business
"Mr. Rabinovich's recent purchase of XTL shares in the market and his investment in InterCure is a resounding vote of confidence from our largest...
Business
New Teva CEO Kare Schultz will earn an annual salary of $2 million and a performance-dependent bonus of 140% - and up to a...